Dr Hunter is an experienced Pharmaceutical/Biotech executive with over 29 years experience of taking projects in small molecules and biologics from concept to human proof of concept. He is experienced in the management of the drug discovery and development process covering all aspects of non clinical and clinical development.
He has served as Director of Discovery and Development at Atopix Therapeutics and Oxagen Ltd where he has managed the CRTH2 antagonist program from concept to Phase IIb clinical trials covering all discovery and development. He was involved in transitioning Oxagen from a platform genetics company to a drug development company and has been involved in multiple VC financing rounds and Pharma due diligence processes. He is experienced at board level.
Dr Hunter has also held positions at British Biotech Pharmaceuticals (now Vernalis PLC) and at GD Searle Pharmaceuticals Ltd. He received his BSc in Biochemistry from the University of Leeds and a PhD in Molecular Biology and Genetics from the University of Nottingham.